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Abstract A wide variety of cardiac disease states can
induce remodelling and lead to the functional consequence
of heart failure. These complex disease states involve a
plethora of parallel signal transduction events, which may
be associated with tissue injury or tissue repair. Innate
immunity is activated in hearts injured in different ways,
evident as cytokine release from the heart, activation
of toll-like receptors involved in recognizing danger, and
activation of the transcription factor nuclear factor kappa
B. Nuclear factor kappa B regulates gene programmes
involved in inflammation as well as the resolution of
inflammation. The impact of this is an enigma; while
cytokines, toll-like receptors, and nuclear factor kappa B
appear to elicit myocardial protection in studies of pre-
conditioning, the literature strongly indicates a detrimental
role for activation of innate immunity in studies of acute
ischaemia–reperfusion injury. The impact of activation of
cardiac innate immunity on the long-term outcome in in
vivo models of hypertrophy and remodelling is less clear,
with conflicting results as to whether it is beneficial or
detrimental. More research using genetically engineered
mice as tools, different models of evoking remodelling, and
long-term follow-up is required for us to conclude whether
activation of the innate immune system is good, bad, or
unimportant in chronic injury models.
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Background
Heart failure (HF) is a functional consequence of a wide
variety of diseases, including ischaemic heart disease,
congenital disorders, hypertension, valvular heart disease,
postpartum cardiomyopathy, and the complex cardiomy-
opathies where genetic mutations may be contributing
reasons [1–3]. Regardless of etiology, the heart may
respond with remodelling to maintain cardiac function
despite continuous stress. In the 1960s and 1970s,
HF was regarded as a mechanical pump failure and
treated with inotropic and diuretic agents. In the 1980s,
the neurohormonal model of HF was introduced, leading
to clinical treatment with angiotensin-converting enzyme
inhibitors, b-blockers, and aldosterone antagonists. How-
ever, morbidity and mortality of HF still remain high,
indicating that we have not yet fully grasped the mech-
anisms of the underlying pathology and are not able to
prevent remodelling. In the 1990s, the cardioinflamma-
tory model of HF was introduced [3]. Since then, a large
number of publications have documented the activation
of the innate immune system in heart failure patients.
Patients with HF have increased circulating levels of
inflammatory cytokines, immune activity in the heart
itself, and in circulating blood cells. Whether this is a
cause or consequence of disease is currently not known.
Patients with inflammatory disease (i.e. inflammatory
joint disease, inflammatory bowel disease and HIV infec-
tions) have increased incidence of cardiovascular dis-
ease, indicating that the events leading to remodelling
of the heart may be due to systemic effects driven by
the immune system [3–6]. The current review aims at
giving an overview of how the innate immune system
regulates cardiac cells in the process of remodelling
towards HF.
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Basic biology of remodelling
Remodelling of the heart as a response to various injuries
contains some specific features; at a macroscopic level, an
increase of cardiac mass takes place before thinning of
the ventricular wall and dilatation [1, 7, 8]. At the cellular
level, many events take place; cardiomyocyte growth;
cardiomyocyte death through apoptosis and autophagy;
and deposition of extracellular matrix. The remodelling
heart turns on foetal gene programmes originally used for
heart formation, which may be responsible for some of
the maladaptive events in the failing heart [1, 2]. Cardiac
cell growth is an important adaptive process to an
increased work load, which ultimately may contribute to
HF [9]. Cardiac cell growth itself is regulated by pro-
teasomes, regulating both proteolysis and protein synthe-
sis in cells on their way to failure development [9, 10].
Apoptosis is the main pathway through which the
organism gets rid of damaged cells, whereas autophagy is
the main way of eliminating or recycling damaged
organelles [9, 11]. Apoptosis and autophagy are part of
normal heart maintenance but are increased in the process
of remodelling [9, 11]. Evidence has existed of apoptosis
in the development of heart failure for some time,
although involving a minority of cells and with an unclear
importance for disease development [7, 12]. Recent
research pinpoints autophagy as an emerging factor con-
trolling remodelling in the process of HF development
[11, 13]. Deposition of extracellular matrix during
remodelling contributes to increased cardiac size and
deteriorating function [1–3]. The innate immune system
may itself influence all these factors which are part of the
remodelling process. The current review will focus on in
vivo evidence linking the innate immune system to
remodelling rather than details on life, death, and growth
of different cells.
Innate immunity
Innate immunity is our first line of defence against foreign
intruders. It is present from birth and is able to recognize
danger ‘‘at a glance’’. The innate immune system consists
of phagocytosing cells such as macrophages, dendritic
cells, and polymorphonuclear granulocytes, as well as
cytokines, chemokines, and activation of the complement
cascade [14–17]. The cells of the innate immune system
recognize conserved motifs on pathogens termed pathogen-
associated molecular patterns (PAMP). Recent evidence
also suggests that the innate immune system recognizes
endogenous danger signals, termed damage-associated
molecular patterns (DAMP) [17, 18]. Polly Matzinger [19]
proposed that the immune system does not discriminate
between self and non-self but reacts upon danger rather
than foreignness. The presence of potentially infectious
PAMP would not necessarily trigger an immune response
unless there is evidence of host tissue injury signified by
alarm signals [18, 19]. Endogenous alarm signals may be
crystalline uric acid, heat shock proteins 60, 70, and 96,
fragments of hyaluronan and fibronectin [20–22]. Poten-
tially other, yet undiscovered, molecules are released
during myocardial remodelling and may act as danger
molecules.
PAMP/DAMP in turn are recognized by pattern recog-
nition receptors (PRR), which may be membrane bound or
cytoplasmatic. A cartoon of the signalling downstream to
PRR is shown in Fig. 1. There are currently four known
families of PRR: The transmembrane protein families
of toll-like receptors (TLR) and C-type lectin receptors
(CLR), as well as cytoplasmatic protein families such as
nucleotide oligomerization domain (NOD)- like receptors
(NLR), and retinoic acid-inducible gene (RIG)-like recep-
tors (RLR) [17]. PRR are present not only in cells of the
innate immune system such as macrophages and dendritic
cells, but also in ‘‘non-professional’’ immune cells. Very
little is currently known about the expression and function
of NLR, CLR, and RLR in the heart, and thus this review
will summarize some of the budding knowledge of TLR
below. The binding of a PAMP to a PRR leads to activation
of different transcription factors through complex signal-
ling pathways, producing substances increasing the defence
against the threatening factor. Nuclear factor kappa B
(NFjB) is one of the most important transcription factors
regulating immune responses downstream to TLR and has
been called the bridge between innate and adaptive
immunity [23].
Adaptive immunity is developed as a result of previous
encounters with pathogens [24]. This form of immunity is
specific, as it will recognize and counteract a pathogen that
has been introduced earlier. The developed immunity lasts
for many years and can therefore be termed to have
memory. Tolerance indicates that the immune system is
able to discriminate between self and non-self. The adap-
tive immune system works mainly through B lymphocytes
and T lymphocytes and is not a subject of the present
review. However, it should be mentioned that a role of
adaptive immunity in remodelling is recently indicated.
Patients with HF due to ischaemic heart disease or dilated
cardiomyopathy have a reduced level of circulating regu-
latory T cells (Tregs), a cell type that suppresses the
immune response [25, 26]. Tregs from HF patients had a
reduced functional capacity to suppress cytokine produc-
tion from CD4 ? CD25- T cells [25, 26]. Transfer of Tregs
to rats with hypertension-induced hypertrophy leads to
reverse remodelling and improved electric remodelling
[27].
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Evidence supporting a role of innate immunity
in myocardial remodelling
Cytokines
Cytokines are signalling molecules sent out by many dif-
ferent cells to attract inflammatory cells to an area under
attack or needing repair. More than 200 cytokines have
been cloned; they are classified into the main families
of IL-2/IL-2 family, IL-6/IL-12 family, interferon-a/b
family, tumour necrosis factor family, IL-10 family, IL-17
family, interleukin-1 family, TGF-b family, and chemokine
family [28, 29]. Cytokines have a plethora of direct bio-
logical effects, as well as indirect effects signalling through
activation of transcription factors. Patients with HF have
increased circulating levels of both pro- and antiinflam-
matory cytokines and their receptors, as recently reviewed
elsewhere [3, 12]. The remodelling heart itself has
increased levels of cytokines [3, 12]. However, we do
currently not know whether the increased cytokine sig-
nalling network in HF patients starts in the heart or in the
periphery [12]. Furthermore, although cytokines have
biological effects on cardiac contractility, extracellular
matrix deposition, and apoptosis induction, their increase
in remodelling could signify both beneficial attempts of
tissue repair and a drive towards tissue injury. Cytokines
such as TNFa, IL-1b, and TWEAK induce activation of
nuclear factor kappa B [3, 12, 30]. Cytokines and their role
for myocardial remodelling are reviewed more extensively
elsewhere in this issue.
Nuclear factor kappa B
The transcription factor NFjB was first discovered as a B
cell-specific DNA-binding protein that binds the kappa
light chain enhancer region. It is implicated in the regula-
tion of many disease states and biological phenomenon,
where pathophysiologists usually regard its actions with
suspicion and has researched it as the major culprit
underlying injury. In research environments engaged in
mechanisms of cell death, NFjB is regarded as a survival
factor [7, 31]. For reviews on NFjB and the heart, see
references [32–35]. The NFjB family consists of the
members p50–p105, p52–p100, p65/RelA, c-Rel, and
RelB. Different members can form various homo- and
heterodimers, and the composition of the dimer will
determine its action. In resting cells, NFjB is found in an
inactive form in the cytoplasm. It is bound to a group of
inhibitory proteins called IjB. IjB may be phosphorylated
by different upstream kinase cascades called IKK1/IKKa
and IKK2/IKKb, after which IjB is ubiquinated and
releases NFjB (Fig. 1). Ubiquitinated IjB is degraded in
the proteosome [9]. When released, NFjB translocates to
the nucleus where it can activate gene programs. Although
more than 400 genes may be regulated by NFjB, the
most relevant groups of genes in this context are cyto-
kines, leucocyte adhesion molecules, interleukins, matrix
metalloproteinases, and various genes regulating apoptosis.
It should also be noted that NFjB also regulates genes
associated with the resolution of inflammation, such as
manganese superoxide dismutase, inducible nitric oxide
synthase, and inducible cyclooxygenase [31]. Due to the
diversity of the NFjB dimer and its regulatory proteins as
well as the diversity in the nature of the stimuli leading to
remodelling, the activities and amounts of transcribed
Fig. 1 Toll-like receptors (TLR) recognize pathogen-associated
molecular patterns (PAMP) or endogenous damage-associated molec-
ular patterns (DAMP). Ligand stimulation recruits adaptor molecules
TIRAP (TIR domain-containing adaptor protein) or TRAM (TRIF-
related adaptor molecule). TLR signal either through the adaptor
molecule MyD88 leading to activation of nuclear factor kappa B
(NFjB) or independent of MyD88, leading to activation of interferon
regulatory factor (IRF3). Abbreviations; AP1 transcription factor
activator protein 1, IjB inhibitor of NFjB, IFN interferon gamma, IKK
inhibitor of NFjB kinase type a, b, and e, IRAK interleukin 1 receptor-
associated kinases 1 and 4, MAPK mitogen-activated protein kinases,
NEMO inhibitor of NFjB kinase type c, dsRNA double-stranded RNA,
RIP1 receptor-interacting protein 1, TAB TAK-binding proteins, TAK
transforming growth factor beta–activated kinases, TBK1 serine-
threonine protein kinase, TRAF6 tumour necrosis factor receptor–
associated factor 6, TRIF TIR domain containing adaptor–inducing
interferon b. Ub denotes ubiquitination, P denotes phosphorylation
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product after NFjB activation will have many possible
outcomes [31–35].
Nuclear factor kappa B and myocardial remodelling
NFjB is activated in the heart in many conditions, where
the outcome for heart function and cell viability is not
clarified and probably not uniform, summarized in the
cartoon of Fig. 2. NFjB is activated in the heart during
acute ischaemia and reperfusion [36–38]. NFjB is also
activated in the heart [39] and in circulating white blood
cells [40] during unstable angina. Blocking of NFjB
reduces ischaemia–reperfusion injury in experimental
studies with short times of observation [41–43]. NFjB is
activated in the heart by preconditioning, where it is sug-
gested to play a beneficial role for adaptation to ischaemia
[34, 35, 39]. Wong et al. [44] showed for the first time that
NFjB was activated in cardiomyocytes in failing hearts of
patients with ischaemic heart disease, while similarly an
increased NFjB expression was present in the fibrotic areas
in patients with dilated cardiomyopathy. Later studies have
confirmed that NFjB and its target genes are activated in
cardiomyocytes of patients with failing hearts of various
etiologies [45, 46] and that the same is the case in mouse
and rat models of heart failure [22]. Interestingly, NFjB is
also activated in peripheral white blood cells in patients
with failure, except in cachectic patients [47, 48].
Furthermore, fatigued skeletal muscle in heart failure
patients has increased NFjB activation [49]. Thus,
although it is sure that NFjB is activated in human and
animal myocardium during remodelling, the relationship
between heart and periphery is far from clarified.
Quite a few researchers have tried to elucidate what
NFjB does in the heart in the remodelling process, but with
conflicting results. Mice with targeted deletion of the p50
NFjB subunit (but with normal p65 expression) subjected
to myocardial infarction had an increased remodelling in
the form of larger end-diastolic volume and reduced ejec-
tion fraction compared to wild type [50]. The p50 KO had
an increased inflammatory response in the form of higher
macrophage infiltration, higher expression of the chemo-
attractant MCP-1, higher TNFalpha, and IL-6 expression in
the infarcted myocardium, and higher matrix metallopro-
teinase activity [50]. These data, indicating a beneficial
effect of the p50 subunit during cardiac remodelling, fit the
concept that the p50 homodimer is actually a repressor of
transcription [31]. However, other groups have reported
different findings in the p50 KO. Frantz et al. [51] found
that postinfarct, p50 KO hearts had preserved ventricu-
lar dimensions, less matrix metalloproteinase expression,
reduced collagen deposition, but higher TNFalpha expres-
sion. These findings were confirmed by Kawano et al. [52],
who found reduced ventricular rupture, improved systolic
and diastolic dimensions and function, reduced collagen
deposition, and reduced cytokine expression postinfarction
in p50 KO mice. In a model of TNF-induced cardiomyopathy
through cardiac-specific TNFalpha expression, p50 KO mice
had improved diastolic and systolic function, suppressed
matrix metalloproteinase activity and expression, and
improved survival in male mice [53].
Other approaches have been performed to suppress
NFjB activation in vivo. Gupta et al. [54] used a model of
hypertrophy through cardiospecific overexpression of
myotrophin and delivered short hairpin RNA silencing p65
with a lentiviral vector into hearts. This resulted in a
regression of hypertrophy (heart weight/body weight ratio)
and reduced activation of cardiac NFjB and its target
genes. The same group tested the effect of chronically
inhibiting NFjB through cross-breeding the cardiac spe-
cific myotrophin mouse with a dominant-negative IjBa
mouse [55]. Although the authors have only preliminary
functional data in that study, it is indicated that dominant-
negative IjBa inhibited the activation of NFjB and its
target genes, concomitant with reducing hypertrophy and
improving left ventricular systolic function [55]. In a rat
model of postinfarction heart failure, chronic administra-
tion of an IjB kinase inhibitor, leading to downstream loss
of NFkB activation, marginally improved left ventricular
function and reduced matrix metalloproteinase activity
28 days later [56]. In contrast, Hikoso et al. [57] made a
cardiospecific knock down of IKKb, a kinase that phos-
phorylates the inhibitory IjBa, allowing nuclear translo-
cation of the NFjB dimer and activation of gene programs.
Mice with knock down of IKKb had no NFjB activation
after hypertrophy evoked by transaortic banding but had
increased diastolic diameter, reduced fractional shortening,
increased expression of atrial and brain natriuretic peptides
in the left ventricle, and larger cross-sectional area of
cardiomyocytes than banded wild type [57]. In agreement
Fig. 2 A summary of the main discussion in the review; Innate
immunity evident as cytokine release, Toll-like receptor activation, or
nuclear factor kappa activation may lead to beneficial myocardial
adaptation to ischaemia. Cardiac innate immunity increases acute
ischaemic injury. However, its role in long-term chronic models of
remodelling and hypertrophy is not clarified
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with that, Kratsios et al. [58] inhibited NFjB activation by
cardiospecific deletion of NEMO, a regulatory subunit of
the IKKc complex. NEMO-deleted mice developed spon-
taneous hypertrophy progressing with age. When NEMO
knockouts were subjected to transaortic banding, the mal-
adaptive left ventricular remodelling escalated compared to
wild types or NEMO KO without pressure overload [58].
In both of these papers, antioxidant status evident as lack of
manganese superoxide dismutase or nitric oxide synthase
appears crucial to the negative effects evoked by inhibition
of NFjB activation [59, 60].
Thus, there is no doubt that NFjB is activated in hearts
of patients, rats, and mice during remodelling after various
forms of injury. However, the impact of this activation is
not clear at the time being and warrants further research
with focus on the composition of the NFjB dimer and
downstream biological effects.
Toll-like receptors
In 1997, vertebrate homologues of the Drosophila spp.
transmembrane PRR ‘Toll’ were identified and termed
the Toll-like receptors [14–17]. To date, 11 human and
13 mouse TLR have been cloned [17, 22]. TLR recog-
nize pathogens and possibly endogenously produced
ligands as well and activate the immune system through
a signalling pathway down to NFjB or interferon regu-
latory factor 3.
The ligands for TLR are molecular motifs associated
with pathogens. TLR types 1, 2, 4, and 6 mainly recognize
lipopeptides that are components of bacterial cell walls.
TLR2 recognizes components of both gram-positive and
gram-negative bacteria, in addition to components from
fungi, parasites, and viruses. TLR4 recognizes cell wall
components of gram-negative bacteria, LPS. TLR types 3,
7, 8, and 9 are named antiviral TLRs and recognize viral
components or single-/double-stranded RNA/DNA. TLR5
binds protein ligands, such as flagellin from fungi [14–17].
Also endogenous activators of TLRs have been suggested
(DAMP). Among these are heat shock proteins 60, 70, and
96, fibrinogen, heparan sulphate, and hyaluronan fragments
[20, 22].
When activated, the TLR signalling network controls
the initiation, maintenance, modulation, and termination of
innate host defences by several mechanisms [14–17]. TLR
activation leads to the production of cytokines and anti-
microbial molecules, which in turn activate cellular
immune components such as macrophages. Activated TLR
on dendritic cells induce cell maturation, and the activated
dendritic cells stimulate T-cell expansion and differentia-
tion. TLR also induce the expression of costimulatory
molecules necessary for sustained activation of adaptive
immunity. TLR2 and TLR4 are the most well studied in the
context of the heart.
The structure of TLRs and downstream signalling path-
ways have recently been reviewed elsewhere [17, 22, 24].
Briefly, signalling most frequently happens through the
adaptor molecule MyD88 (myeloid differentiation primary
response protein 88) [14–17]. Other adaptor molecules
include TIRAP (TIR domain-containing adaptor protein),
TRIF (TIR domain-containing adaptor inducing interferon
b), and TRAM (TRIF-related adaptor molecule). MyD88-
dependent signalling via TLR2 and TLR4 requires the
presence of TIRAP and will end after several steps in acti-
vation of NFjB and subsequent gene transcription (Fig. 1)
[14–17]. MyD88-independent signalling involves the adap-
tor proteins TRIF or TRAM. TLR4 can activate TRIF-
dependent pathways without MyD88 association, leading to
activation of the transcription factor IRF3, in turn producing
interferon and costimulatory molecules.
Toll-like receptors and myocardial remodelling
TLR types 2, 3, 4, and 6 are expressed in cardiac myocytes
[20, 22]. TLR are emerging as important regulators of
pathophysiological processes in the heart but have been
more studied in acute pathologies than in studies relevant
to remodelling. For instance, in patients with acute myo-
cardial infarction, TL4 signalling is activated, and this
appears to lead to increased cytokine release [59]. TLR4 is
increasingly expressed in peripheral monocytes from
patients with acute myocardial infarction, a finding that
was accompanied by increased cytokine release [59]. The
TLR4 activation was highest in patients with acute heart
failure [59]. Frantz et al. [60] demonstrated that injured
human and murine myocardium exhibit focal areas of
intense TLR4 expression. Other findings suggesting a role
of TLR4 in myocardial ischaemia–reperfusion injury are
the observations that the TLR4 ligand LPS is a possible
preconditioning stimulus. Several researchers suggest that
systemic administration of sublethal doses of LPS or
monophosphoryl lipid A (a partial structure of the lipid A
moiety of gram-negative LPS) protects the myocardium
against subsequent ischaemia and reperfusion injury
[61–63]. In greater doses, LPS leads to myocardial
depression, and this effect is dependent of TLR4-mediated
signalling [64, 65]. TLR2 has anti-apoptotic effect in
stressed or injured cardiac myocytes, as inhibition of TLR2
enhances stress-induced cytotoxicity [66]. TLR2-deficient
mice are also protected against postischaemic coronary
endothelial dysfunction [67]. When TLR2 knockout mice
were injected with doxorubin to induce remodelling, they
had better left ventricular function, blunted NFkB activa-
tion, and less apoptosis than hearts of wild types 5 days
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after treatment [68]. Experiments carried out in TLR4-
deficient mice have shown that these mice develop smaller
infarcts after myocardial infarction than wild-type mice in
short times of observation [69, 70].
However, when it comes to studies of in vivo myocar-
dial remodelling with long-term follow-up, the role of
TLRs for remodelling is more scarce. Ha et al. [71] sub-
jected TLR4 knockout mice to aortic banding for 2 weeks
and found that TLR4-deleted mice had less remodelling of
the left ventricle. Timmers et al. [72] induced myocardial
infarction in TLR4 knockout mice and found that as
opposed to sham-operated mice or wild types of a different
strain, TLR4 knockouts had preserved left ventricular
function postinfarct 28 days later. Interstitial fibrosis and
hypertrophy were reduced in the non-infarcted heart tissue
of knockouts [72]. In the infarcted myocardium, the
inflammatory response was reduced in the knockouts
[72]. In contrast, in a model of aortic constriction in rats,
activation of TLR4 signalling reduced the hypertrophy
response, an effect that was reversed through administrat-
ing a TLR4 antagonist [73]. Cardiac fibrosis was reduced
through inducing TLR4 signalling [73]. Shishido et al. [74]
used TLR2-deficient mice with coronary artery ligation and
followed them for 4 weeks. The knockouts had a higher
survival after ligation than wild types, less remodelling as
evaluated by echocardiography, less myocardial fibrosis,
but no differences in infarct size or accumulation of
polymorphonuclear granulocytes in the heart.
Thus, in order to determine more firmly whether TLR2
or 4 (or other TLR) are important for myocardial remod-
elling, more evidence is needed from knockout mice using
different forms of cardiac injury, and longer times of
observations of ventricular remodelling.
Future perspectives
A large body of evidence suggests that innate immunity is
involved in the signalling underlying cardiac pathologies
through cytokines such as TNFa and IL-6. Involvement of
innate immunity is indicated through NFrB and TLR in
models of acute myocardial injury. However, the impor-
tance of both NFkB and TLR in the chronic context of
myocardial remodelling is far from determined. Use of
knockout mice of different genetic backgrounds, careful
experimental design with follow-up for at least 6 weeks
after the index event and use of different models to evoke
remodelling may give us a fuller understanding of these
complex signalling cascades in the future. We still have the
possibility that activation of innate immunity in acute and
chronic cardiac injury is just an attempt to repair damaged
tissue and is a beneficial process counteracting the viscious
circle of heart failure development. The role of innate
immunity in the heart versus the periphery during cardiac
remodelling needs more attention.
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